Vertaling van "risk of transmission from a non-isolated " (Nederlands → Frans) :

The risk of transmission from a non-isolated patient is 16 to 38 times 11,12 higher than from isolated patients.
Le risque de transmission à partir d'un patient non isolé est 16 à 38 fois plus élevé qu’à partir de patients isolés 11,12 .

Intervention When a MRSA colonised or infected patient leaves the hospital to receive ambulatory care, it is recommended that the general practitioner be fully informed of the follow-up of MRSA colonisation or infection through the discharge medical report and any additional standard document Patients recently hospitalised for more than 24 hours or transferred from another hospital or presenting risk factors for MRSA colonisation must be isolated.
Quand le patient colonisé ou infecté par MRSA quitte l’hôpital pour recevoir des soins ambulatoires, il est conseillé d’informer de manière complète le médecin généraliste du suivi de la colonisation ou de l’infection à MRSA au moyen du rapport médical de renvoi ou de tout document standard supplémentaire.

Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model.
Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure : estimates based on a model.

Results from the Japanese KYOTO HEART study, presented in September at the European Society of Cardiology Congress, demonstrated that the addition of Diovan to a non-ARB-based treatment regimen for high blood pressure provided a significant 45% relative risk reduction in cardiovascular events, including stroke, over a conventional non-ARB treatment regimen.
Les résultats de l’étude japonaise KYOTO HEART, présentés au Congrès de la Société Européenne de Cardiologie, ont prouvé que l’adjonction de Diovan lors d’un traitement contre l’hypertension non basé sur les ARA a conduit à une réduction importante de 45% du risque relatif d’accidents cardiovasculaires, notamment cérébraux, par rapport à un traitement non ARA conventionnel.